Skip to main content
Top
Published in: Osteoporosis International 12/2016

01-12-2016 | Original Article

Effect of intravenous zoledronic acid infusion on electrocardiographic parameters in patients with osteoporosis

Authors: I. Aktas, C. Nazikoglu, A. Kepez, F. U. Ozkan, M. Y. Kaysin, P. Akpinar, Z. Dogan, C. Ileri, S. Saymaz, O. Erdogan

Published in: Osteoporosis International | Issue 12/2016

Login to get access

Abstract

Summary

We evaluated the effects of zoledronic acid (ZA) therapy on electrocardiographic (ECG) parameters for the first time in the literature. Measurements were performed on ECGs obtained before and after ZA infusion on the same day as well as 1 month after the infusion. ZA infusion did not have any short- or long-term effect on any parameter that might be associated with the tendency for atrial fibrillation or ventricular arrhythmias.

Introduction

The aim of the present study was to evaluate the early and late effects of ZA therapy on ECG parameters which might be associated with the tendency for atrial and ventricular arrhythmias.

Methods

Consecutive patients with osteoporosis who were admitted to our clinic between December 2013 and December 2014 and who were scheduled to receive ZA infusion constituted our study population. Twelve-lead surface ECGs were obtained from all patients before and after ZA infusion on the same day as well as 1 month after the infusion. All ECG parameters were measured and compared with each other for each patient.

Results

Data of 100 patients were used in the analysis (9 male; 70.5 ± 11.6 years of age). There were no significant differences between repeated measurements regarding pmax, pmin, and p dispersion values. QT max and QT min values were significantly increased after infusion; however, there were no significant changes in QT dispersion, Tp-e interval, and Tp-e dispersion values.

Conclusions

ZA infusion did not affect P wave dispersion both at the immediate post-infusion period and 1 month after infusion. QT values were significantly increased early after ZA infusion; however, there were no significant differences in parameters reflecting disparity of ventricular recovery times and transmural dispersion of ventricular repolarization. Based on these observations, it may be suggested that ZA infusion did not have any short- or long-term effect on any parameter that might be associated with the tendency for atrial fibrillation or ventricular arrhythmias.
Literature
1.
go back to reference Dalle Carbonare L, Zannatta M, Gasparetto A, Valenti MT (2010) Safety and tolerability of zoledronic acid and other biphosphonates in osteoporosis management. Drug Healtc Patient Saf 2:121–137CrossRef Dalle Carbonare L, Zannatta M, Gasparetto A, Valenti MT (2010) Safety and tolerability of zoledronic acid and other biphosphonates in osteoporosis management. Drug Healtc Patient Saf 2:121–137CrossRef
2.
go back to reference Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822CrossRefPubMed Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822CrossRefPubMed
3.
go back to reference Pazianas M, Compston J, Huang CL (2010) Atrial fibrillation and biphosphonate therapy. J Bone Miner Res 25:2–10CrossRefPubMed Pazianas M, Compston J, Huang CL (2010) Atrial fibrillation and biphosphonate therapy. J Bone Miner Res 25:2–10CrossRefPubMed
4.
go back to reference Konsta M, Bournia VK, Dania V, Iliopoulos A (2014) Atrial fibrillation following intravenous zolendronic acid for osteoporosis. J Clin Rheumatol 20:239–240CrossRefPubMed Konsta M, Bournia VK, Dania V, Iliopoulos A (2014) Atrial fibrillation following intravenous zolendronic acid for osteoporosis. J Clin Rheumatol 20:239–240CrossRefPubMed
5.
go back to reference Sharma A, Chatterjee S, Arbab-Zadeh A, Goyal S, Lichstein E, Ghosh J, et al. (2013) Risk of serious atrial fibrillation and stroke with use of biphosphonates. Chest 144:1311–1322CrossRefPubMed Sharma A, Chatterjee S, Arbab-Zadeh A, Goyal S, Lichstein E, Ghosh J, et al. (2013) Risk of serious atrial fibrillation and stroke with use of biphosphonates. Chest 144:1311–1322CrossRefPubMed
6.
go back to reference Sharma A, Einstein AJ, Vallakati A, Arbab-Zadeh A, Walker MD, Mukherjee D, et al. (2014) Risk of atrial fibrillation with use of oral and intravenous bisphosphonates. Am J Cardiol 113:1815–1821CrossRefPubMed Sharma A, Einstein AJ, Vallakati A, Arbab-Zadeh A, Walker MD, Mukherjee D, et al. (2014) Risk of atrial fibrillation with use of oral and intravenous bisphosphonates. Am J Cardiol 113:1815–1821CrossRefPubMed
7.
go back to reference Bonilla IM, Vargas-Pinto P, Nishijima Y, Pedraza-Toscano A, Ho HT, Long VP 3rd, et al. (2014) Ibandronate and ventricular arrhythmia risk. J Cardiovasc Electrophysiol 25:299–306CrossRefPubMed Bonilla IM, Vargas-Pinto P, Nishijima Y, Pedraza-Toscano A, Ho HT, Long VP 3rd, et al. (2014) Ibandronate and ventricular arrhythmia risk. J Cardiovasc Electrophysiol 25:299–306CrossRefPubMed
8.
go back to reference Ilgezdi ZD, Aktas I, Metin FD, Kepez A, Ozkan FU, Silte AD, et al. (2015) Acute effect of zoledronic acid infusion on atrial fibrillation development in patients with osteoporosis. Anatol J Cardiol 15:320–324CrossRefPubMed Ilgezdi ZD, Aktas I, Metin FD, Kepez A, Ozkan FU, Silte AD, et al. (2015) Acute effect of zoledronic acid infusion on atrial fibrillation development in patients with osteoporosis. Anatol J Cardiol 15:320–324CrossRefPubMed
9.
go back to reference Howard PA, Barnes BJ, Vacek JL, Chen W, Lai SM (2010) Impact of biphosphonates on the risk of atrial fibrillation. Am J Cardiovasc Drugs 10:359–367CrossRefPubMed Howard PA, Barnes BJ, Vacek JL, Chen W, Lai SM (2010) Impact of biphosphonates on the risk of atrial fibrillation. Am J Cardiovasc Drugs 10:359–367CrossRefPubMed
10.
go back to reference Aytemir K, Ozer N, Atalar E, Sade E, Aksoyek S, Ovunc K, et al. (2000) P wave dispersion on 12-lead electrocardiography in patients with paroxysmal atrial fibrillation. Pacing Clin Electrophysiol 23:1109–1112CrossRefPubMed Aytemir K, Ozer N, Atalar E, Sade E, Aksoyek S, Ovunc K, et al. (2000) P wave dispersion on 12-lead electrocardiography in patients with paroxysmal atrial fibrillation. Pacing Clin Electrophysiol 23:1109–1112CrossRefPubMed
11.
go back to reference Tisdale JE, Allen MR, Overholser BR, Jayner HA, Kovacs RJ (2015) Influence of zoledronic acid on atrial electrophysiological parameters and electrocardiographic measurements. J Cardiovasc Electrophysiol 26:671–677CrossRefPubMedPubMedCentral Tisdale JE, Allen MR, Overholser BR, Jayner HA, Kovacs RJ (2015) Influence of zoledronic acid on atrial electrophysiological parameters and electrocardiographic measurements. J Cardiovasc Electrophysiol 26:671–677CrossRefPubMedPubMedCentral
12.
go back to reference Antzelevitch C, Shimizu W, Yan GX, Sicouri S (1998) Cellular basis for QT dispersion. J Electrocardiol 30:168–175CrossRefPubMed Antzelevitch C, Shimizu W, Yan GX, Sicouri S (1998) Cellular basis for QT dispersion. J Electrocardiol 30:168–175CrossRefPubMed
13.
go back to reference Kors JA, Ritsema van Eck HJ, van Herpen G (2008) The meaning of the Tp-Te interval and its diagnostic value. J Electrocardiol 41:575–580CrossRefPubMed Kors JA, Ritsema van Eck HJ, van Herpen G (2008) The meaning of the Tp-Te interval and its diagnostic value. J Electrocardiol 41:575–580CrossRefPubMed
Metadata
Title
Effect of intravenous zoledronic acid infusion on electrocardiographic parameters in patients with osteoporosis
Authors
I. Aktas
C. Nazikoglu
A. Kepez
F. U. Ozkan
M. Y. Kaysin
P. Akpinar
Z. Dogan
C. Ileri
S. Saymaz
O. Erdogan
Publication date
01-12-2016
Publisher
Springer London
Published in
Osteoporosis International / Issue 12/2016
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-016-3684-6

Other articles of this Issue 12/2016

Osteoporosis International 12/2016 Go to the issue